Search Results
Search results for "Juan Jose Fung"
Results found for "Juan Jose Fung"
- Crinetics Presents Clinical And Research Results At ENDO 2022
cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Orthosteric dose increases drive continuously stronger responses; NAMs and PAMs have structural ceilings complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve so far—dose Ranking Partial Agonists Without Losing Meaning Chemists want a single number.
- đź“° GPCR Weekly News, August 14 to 20, 2023
Complex in Stress and Anxiety Disorders GPCRs in Oncology and Immunology Exacerbating effects of single-dose by the American College of Clinical Pharmacology Sosei and Cancer Research UK announce first patient dosed
- Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine..
In a LPS-induced lung inflammation model in mice, ACT-660602 led to significantly reduced recruitment of the CXCR3+ CD8+ T cell in the bronchoalveolar lavage compartment when administered orally at a dose
- Addex raises $4.2 million in equity financing
development, today announced that it has entered into a definitive agreement with Armistice Master Fund Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded
- Addex Raises $10 Million In Equity Financing
9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise
- Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric...
Such studies revealed that tissue response to a given dose of the hormone or its antagonist depends on
- Coincident Regulation of PLCβ Signaling by Gq-Coupled and μOpioid Receptors Opposes Opioid- Mediated
Ultimately this could lead to identification of new non-MOR targets that would allow for lower dose utilization
- đź“° GPCR Weekly News, June 26 to July 2, 2023
Let's gather 'round for our weekly dose of GPCR News. Congratulations to our Dr. Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
The PVT appears to provide stimulus salience encoding in a dose- and NPS-dependent manner.
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent ÂŁ388 million on Much of that funding is distributed to support third party research, but the group also does its own
- 🤯Mind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⦿ Nov 18 - 24, 2024
Recursion and Exscientia have merged to enhance drug discovery GPCR Classes Pathios Therapeutics Announces Dosing models of physiological ligand complexes Reviews, GPCRs, and more Sensing host and environmental cues by fungal
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
Investors don’t fund complexity. They fund momentum. When your team is aligned, you move faster without more funding. You adapt quicker without losing direction.
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
This has implications for everything from dosing frequency  to resistance barriers  in infectious disease
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
How It Worked BMS funded the research, salary, and even tuition UConn accepted the research done in the
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund
- Chemokine receptor-targeted drug discovery: progress and challenges
antibody mogamulizumab has also been approved in Japan and by the FDA for the treatment of mycosis fungoides molecular redundancy, pointing out that, in some cases, inappropriate target selection and insufficient dosing
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Extracts from plants, fungi, bacteria, and environmental microorganisms provided the first potent modulators Less than ~15% of higher plant species, <5% of bacterial and fungal species, and only a fraction of marine
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
Irreversible modifications pose ongoing risks for safety profiles Proactive detection methodology arms discovery teams with actionable insight Pharmacokinetic and High-Dose Investigations Regulatory guidance
- How Schild Analysis Protects Your Conclusions in GPCR Research
Apply dose-ratios and Schild regressions to derive Kᴮ or pA₂ values that won’t collapse under scrutiny
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
That kind of street-level data shapes everything: dosing strategies that reflect actual potencies in
- Nanobodies: New Dimensions in GPCR Signaling Research
J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F.
- đź“° GPCR Weekly News, October 9 to 15, 2023
Modes of Action A non-pheromone GPCR is essential for meiosis and ascosporogenesis in the wheat scab fungus
- The Hidden Cost of Ambition in Biotech Leadership
When leaders make those trade-offs visible and deliberate , the organization gains focus without losing execution and concentrating resources, the company increases the probability that future expansion will be funded Investors fund companies that demonstrate controlled expansion.
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
a patient with a specific variant of the β2AR gene that reduces potency might require a higher drug dose evolutionary conservation of these residues can lead to the development of drugs that are less likely to lose
- 4GPCRnet, September 26-29, 2022. Leipzig, Germany
Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded
- đź“° GPCR Weekly News, August 7 to 13, 2023
Financial Results And Provides Corporate Update Sosei Heptares and Cancer Research UK Announce the Dosing
- Curve Shifts Don’t Lie, But Your Eyes Might
Sometimes you’re working with linear fits: Schild plots, dose ratios, regression models.
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
A substantial rightward shift in a dose–response curve is frequently interpreted as competitive antagonism













